Forxiga approved in China for heart failure
4 February 2021 07:00 GMT Forxiga approved in China for heart failure Forxiga is the first SGLT2 inhibitor approved in China for heart failure withreduced ejection fraction in adult patients with and without type-2 diabetes AstraZeneca's Forxiga (dapagliflozin) has been approved in China to reduce the risk of cardiovascular (CV) death and hospitalisation for heart failure (hHF) in adults with heart failure (NYHA class II-IV) with reduced ejection fraction (HFrEF). Heart failure (HF) is a life-threatening chronic disease that prevents the heart from pumping sufficient levels of